US Patent Issued to Shanghai Annova Biotechnology on Oct. 7 for "Substituted morpholines as ATR kinase inhibitors" (Chinese Inventor)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,435,095, issued on Oct. 7, was assigned to Shanghai Annova Biotechnology Co. Ltd. (Shanghai).

"Substituted morpholines as ATR kinase inhibitors" was invented by Kai Long (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "A substituted fused heterocyclic compound, and a preparation method therefor and the use thereof. Provided is a compound having the structure of formula I or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof can be used as an ATR inhibitor, which has a high activity."

The patent was filed on Dec. 19, 2022, under Application No. 18/723,033.

*For further information, including ...